| Literature DB >> 35087166 |
Parvin Mirmiran1, Firoozeh Hosseini-Esfahani2, Zohreh Esfandiar1, Somayeh Hosseinpour-Niazi1, Fereidoun Azizi3.
Abstract
Cardiovascular disease (CVD), as the leading cause of death worldwide, is the collective term named for disorders afflicting the blood vessels and heart. Inflammation and enhanced oxidative stress have been shown as fundamental risk factors in the onset and progression of CVD. Chronic inflammatory conditions attenuate blood levels of antioxidants because of the continuous generation of elevated levels of reactive oxygen species (ROS). A sufficient intake of antioxidants is also suggested to beneficially interfere with CVD by quenching ROS. Antioxidant vitamins and minerals, such as vitamins A, E, and C, and zinc may slow the development and progression of CVD. This study aimed at investigating the association between daily consumption of dietary vitamins A, E, and C, and zinc and the incidence of CVD. Eligible adults (n = 5102) aged ≥ 30 years, were selected from the participants of the Tehran lipid and glucose study with an average follow-up of 5.3 years. Dietary intake was assessed using a valid and reliable semi-quantitative food frequency questionnaire. Anthropometrics and biochemical variables were evaluated at baseline and follow-up examinations. Multivariable Cox proportional hazard regression models were used to estimate the development of CVD associated with total intakes of vitamins A, E, and C, and zinc. This study was conducted on 2253 men and 2849 women aged 47.0 ± 11.6 and 45.6 ± 10.5 years, respectively. The main sources of dietary vitamins A, E, and C and zinc were fruits, vegetables, and legumes. Risk of CVD decreased from quartile 1 to quartile 4 for vitamin E intake (HR 1.00, 0.91, 0.77, and 0.57; Ptrend = 0.03). The association between the risk of CVD and quartiles of vitamins A, and C and zinc intake was not statistically significant. Our study suggests an inverse association between vitamin E intake and the risk of CVD, emphasizing the potential protective role of fruit and vegetable in the prevention of CVD.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35087166 PMCID: PMC8795399 DOI: 10.1038/s41598-022-05632-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Outline of study participants’ selection.
Baseline characteristics of adult participants of the Tehran Lipid and Glucose Study.
| Total sample | Men | Women | ||
|---|---|---|---|---|
| N = 5102 | N = 2253 | N = 2849 | ||
| Baseline age (years) | 46.2 ± 11.1* | 47.0 ± 11.6 | 45.6 ± 10.5 | < 0.001 |
| Current smokers (%) | 19.1 | 34.8 | 6.7 | < 0.001 |
| Physical activity (MET/min/week) | 524 ± 793 | 588 ± 844 | 473 ± 687 | < 0.001 |
| BMI (Kg/m2) | 28.1 ± 4.5 | 27.1 ± 4.0 | 28.8 ± 4.8 | < 0.001 |
| Waist circumference (cm) | 93.8 ± 11.0 | 96.5 ± 10.3 | 91.8 ± 11.4 | < 0.001 |
| SBP (mmHg) | 114 ± 16.7 | 118 ± 15.9 | 112 ± 17.1 | < 0.001 |
| DBP (mmHg) | 76.3 ± 10.2 | 78.7 ± 10.3 | 74.4 ± 10.2 | < 0.001 |
| Total cholesterol (mg/dl) | 219 ± 121 | 234 ± 138 | 207 ± 117 | < 0.001 |
| LDL (mg/dl) | 118 ± 31 | 118 ± 31 | 118 ± 32 | 0.51 |
| TG/HDL-ratio | 3.8 ± 3.0 | 4.6 ± 3.7 | 3.1 ± 2.4 | < 0.001 |
| FPG (mg/dl) | 98.1 ± 26.6 | 99.3 ± 26.2 | 97.2 ± 27.0 | 0.007 |
| 2 h- plasma glucose (mg/dl) | 108 ± 43.1 | 106 ± 44.5 | 110 ± 40.3 | 0.004 |
| Energy intake (kcal/day) | 2314 ± 714 | 2416 ± 728 | 2230 ± 695 | < 0.001 |
| Carbohydrate (% of energy) | 58.5 ± 8.3 | 59.9 ± 6.4 | 57.5 ± 9.5 | < 0.001 |
| Protein (% of energy) | 14.6 ± 5.2 | 14.4 ± 2.7 | 14.7 ± 8.1 | 0.19 |
| Total fat (% of energy) | 30.4 ± 10.3 | 28.7 ± 6.0 | 31.8 ± 17.6 | < 0.001 |
| SFA (% of energy) | 10.1 ± 11.1 | 9.5 ± 2.7 | 10.6 ± 16.9 | 0.003 |
| MUFA (% of energy) | 10.4 ± 11.3 | 9.7 ± 2.6 | 10.9 ± 16.9 | < 0.001 |
| PUFA (% of energy) | 6.3 ± 12.1 | 5.8 ± 1.9 | 6.7 ± 16.9 | < 0.001 |
| Fiber (g/1000 kcal) | 9.7 ± 3.3 | 9.0 ± 2.8 | 10.2 ± 3.8 | < 0.001 |
| Vitamin E (mg/day) | 12.1 ± 5.3 | 11.2 ± 5.0 | 12.8 ± 44.5 | 0.08 |
| Vitamin C (mg/day) | 170 ± 123 | 160 ± 108 | 178 ± 130 | < 0.001 |
| Vitamin A (µg/day) | 600 ± 371 | 565 ± 350 | 629 ± 399 | < 0.001 |
| Zinc (mg/day) | 13.7 ± 26.3 | 14.0 ± 12.4 | 13.4 ± 45.1 | 0.58 |
MET, metabolic equivalent; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MUFA, mono-unsaturated fatty acids; PUFA, poly-unsaturated fatty acids; SFA, saturated fat.
*Values are mean ± SD unless otherwise listed.
P values derived through Student’s t-test and chi-square test for quantitative and qualitative variables, respectively.
Antioxidant intakes with respect to quartiles of food group consumption.
| Food groups | Vitamin E (mg) | Vitamin C (mg) | Vitamin A (µg) | Zinc (mg) |
|---|---|---|---|---|
| Q1: 0.70 ± 0.27b | 9.7 ± 4.7 | 79.7 ± 44.1 | 421 ± 256 | 11.3 ± 8.1 |
| Q2: 1.60 ± 0.27 | 10.8 ± 10.8 | 123 ± 36.4 | 534 ± 320 | 12.9 ± 10.3 |
| Q3: 2.69 ± 0.38 | 14.0 ± 66.2 | 178 ± 89.0 | 625 ± 351 | 15.3 ± 66.5 |
| Q4: 5.59 ± 2.55 | 14.1 ± 5.0 | 300 ± 137 | 822 ± 446 | 15.1 ± 14.3 |
| P for trendc | < 0.001 | < 0.001 | < 0.001 | 0.01 |
| Q1: 1.89 ± 0.53 | 9.1 ± 4.5 | 101 ± 83.4 | 357 ± 212 | 10.5 ± 8.7 |
| Q2: 3.28 ± 0.36 | 11.0 ± 4.5 | 145 ± 94.4 | 492 ± 213 | 12.2 ± 7.9 |
| Q3: 4.57 ± 0.39 | 12.3 ± 5.3 | 183 ± 92.5 | 632 ± 278 | 13.4 ± 10.3 |
| Q4: 7.66 ± 2.82 | 16.1 ± 66.2 | 251 ± 142 | 920 ± 484 | 18.5 ± 67.3 |
| P for trend | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| Q1: 0.02 ± 0.01 | 11.6 ± 5.3 | 157 ± 126 | 514 ± 341 | 11.6 ± 6.7 |
| Q2: 0.07 ± 0.01 | 11.8 ± 5.6 | 172 ± 122 | 598 ± 389 | 13.0 ± 10.6 |
| Q3: 0.15 ± 0.02 | 11.5 ± 4.8 | 167 ± 107 | 613 ± 360 | 13.7 ± 12.6 |
| Q4: 0.35 ± 0.18 | 13.6 ± 8.2 | 183 ± 132 | 677 ± 407 | 16.4 ± 67.0 |
| P for trend | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| Q1: 0.10 ± 0.07 | 11.2 ± 5.2 | 149 ± 118 | 511 ± 344 | 11.3 ± 8.3 |
| Q2: 0.44 ± 0.13 | 11.6 ± 5.5 | 167 ± 107 | 599 ± 386 | 12.5 ± 8.7 |
| Q3: 1.31 ± 0.43 | 13.5 ± 66.2 | 175 ± 131 | 622 ± 385 | 14.1 ± 13.7 |
| Q4: 5.01 ± 3.79 | 12.5 ± 4.8 | 189 ± 123 | 669 ± 384 | 16.7 ± 66.9 |
| P for trend | 0.25 | < 0.001 | < 0.001 | 0.002 |
| Q1: 4.90 ± 1.34 | 10.6 ± 5.7 | 173 ± 126 | 614 ± 432 | 11.0 ± 8.1 |
| Q2: 7.12 ± 0.72 | 11.3 ± 5.1 | 168 ± 111 | 591 ± 347 | 12.3 ± 10.9 |
| Q3: 10.0 ± 0.95 | 12.0 ± 5.0 | 173 ± 118 | 607 ± 378 | 14.0 ± 12.8 |
| Q4: 16.6 ± 5.29 | 14.6 ± 66.2 | 166 ± 129 | 590 ± 356 | 17.4 ± 66.7 |
| P for trend | 0.02 | 0.007 | 0.004 | < 0.001 |
| Q1: 0.92 ± 0.30 | 12.3 ± 66.3 | 137 ± 119 | 449 ± 325 | 12.5 ± 67.4 |
| Q2: 1.69 ± 0.18 | 11.2 ± 4.6 | 161 ± 108 | 544 ± 332 | 12.2 ± 7.8 |
| Q3: 2.35 ± 0.22 | 11.9 ± 5.0 | 181 ± 125 | 624 ± 344 | 13.6 ± 9.4 |
| Q4: 3.71 ± 1.07 | 13.1 ± 5.5 | 201 ± 123 | 785 ± 326 | 16.2 ± 11.0 |
| P for trend | 0.19 | < 0.001 | < 0.001 | < 0.001 |
| Q1: 0.07 ± 0.03 | 12.0 ± 5.4 | 181 ± 140 | 612 ± 404 | 13.3 ± 9.2 |
| Q2: 0.16 ± 0.02 | 11.7 ± 4.9 | 172 ± 120 | 602 ± 349 | 13.4 ± 12.0 |
| Q3: 0.27 ± 0.04 | 13.4 ± 66.2 | 168 ± 122 | 595 ± 344 | 14.3 ± 66.3 |
| Q4: 0.60 ± 0.32 | 11.5 ± 5.6 | 159 ± 98.6 | 593 ± 416 | 13.8 ± 13.8 |
| P for trend | 0.70 | < 0.001 | 0.12 | 0.32 |
| Q1: 0.41 ± 0.15 | 10.7 ± 4.9 | 148 ± 116 | 499 ± 346 | 11.3 ± 8.3 |
| Q2: 0.84 ± 0.13 | 11.2 ± 4.9 | 161 ± 112 | 554 ± 318 | 12.5 ± 8.7 |
| Q3: 1.32 ± 0.16 | 12.1 ± 5.0 | 174 ± 112 | 627 ± 386 | 14.1 ± 13.7 |
| Q4: 2.92 ± 1.87 | 14.6 ± 66.3 | 197 ± 137 | 722 ± 498 | 16.7 ± 66.9 |
| P for trend | 0.001 | < 0.001 | < 0.001 | < 0.001 |
| Q1: 0.76 ± 0.95 | 13.1 ± 66.1 | 170 ± 131 | 595 ± 382 | 14.2 ± 66.4 |
| Q2: 8.29 ± 2.23 | 11.1 ± 4.6 | 159 ± 117 | 560 ± 376 | 12.7 ± 11.2 |
| Q3: 24.3 ± 7.59 | 11.7 ± 4.8 | 174 ± 122 | 622 ± 380 | 14.1 ± 14.4 |
| Q4: 109 ± 101 | 12.6 ± 5.7 | 176 ± 113 | 626 ± 377 | 13.8 ± 7.6 |
| P for trend | 0.55 | < 0.001 | < 0.001 | 0.68 |
| Q1: 2.13 ± 1.25 | 8.4 ± 3.5 | 138 ± 98 | 497 ± 311 | 11.7 ± 9.8 |
| Q2: 6.27 ± 0.73 | 10.6 ± 3.5 | 163 ± 116 | 563 ± 341 | 13.0 ± 13.2 |
| Q3: 9.26 ± 1.31 | 13.7 ± 65.9 | 184 ± 141 | 641 ± 392 | 15.5 ± 66.5 |
| Q4: 18.62 ± 8.98 | 16.1 ± 6.4 | 196 ± 118 | 703 ± 434 | 14.5 ± 9.3 |
| P for trend | 0.04 | 0.07 | 0.04 | 0.30 |
| Q1: 0.02 ± 0.01 | 11.2 ± 5.1 | 145 ± 109 | 537 ± 379 | 12.5 ± 108 |
| Q2: 0.08 ± 0.01 | 13.6 ± 66.2 | 169 ± 135 | 596 ± 364 | 15.0 ± 66.7 |
| Q3: 0.17 ± 0.03 | 11.7 ± 11.7 | 177 ± 113 | 621 ± 373 | 13.4 ± 11.7 |
| Q4: 0.55 ± 0.42 | 12.0 ± 5.6 | 188 ± 188 | 648 ± 393 | 13.8 ± 10.7 |
| P for trend | 0.96 | < 0.001 | < 0.001 | 0.33 |
| Q1: 200 ± 88.1 | 12.7 ± 66.4 | 156 ± 123 | 549 ± 359 | 14.5 ± 67.2 |
| Q2: 379 ± 112 | 11.5 ± 4.8 | 169 ± 118 | 612 ± 398 | 13.1 ± 11.2 |
| Q3: 679 ± 101 | 12.0 ± 4.6 | 175 ± 121 | 613 ± 342 | 13.5 ± 11.2 |
| Q4: 1342 ± 741 | 12.5 ± 6.3 | 179 ± 121 | 628 ± 383 | 13.6 ± 7.8 |
| P for trend | 0.50 | < 0.001 | 0.001 | 0.97 |
aValues are serving/day, with the exception of sugar-sweetened soft drinks, Tea and coffee.
bData are mean ± SD using ANOVA test.
cP for trend were obtained by the linear regression analysis using the median of each quartile as a continuous variable for each food group.
Figure 2Kaplan–Meier estimates of CVD-free survival according to quartiles of vitamin E intake. P values by log-rank test and number of CVD outcomes recorded in the groups categorized by vitamin E intake.
Figure 3Kaplan–Meier estimates of CVD-free survival according to quartiles of vitamin C intake. P values by log-rank test and number of CVD outcomes recorded in the groups categorized by vitamin C intake.
Figure 4Kaplan–Meier estimates of CVD-free survival according to quartiles of vitamin A intake. P values by log-rank test and number of CVD outcomes recorded in the groups categorized by vitamin A intake.
Figure 5Kaplan–Meier estimates of CVD-free survival according to quartiles of zinc intake. P values by log-rank test and number of CVD outcomes recorded in the groups categorized by zinc intake.
Hazard Ratios (HR) and 95% CIs for cardiovascular diseases according to quartiles of dietary antioxidants intake.
| Variables | Quartiles of intake | ||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | ||
| Median, mg/d | 6.8 | 9.5 | 12.4 | 16.8 | |
| Cases, n | 61 | 56 | 51 | 38 | |
| Person-years, n | 6711 | 6530 | 6593 | 6423 | |
| Follow-up, y | 5.3 | 5.2 | 5.2 | 5.1 | |
| Incidence, % | 9.0 | 8.5 | 7.7 | 5.9 | |
| Crude | 1.00 ref | 0.94 (0.65–1.35) | 0.85 (0.58–1.23) | 0.65 (0.43–0.98) | 0.03 |
| Model adjustedb | 1.00 ref | 0.91 (0.62–1.64) | 0.77 (0.51–1.18) | 0.57 (0.34–0.97) | 0.03 |
| Median, mg/d | 64.7 | 114.2 | 173.3 | 291.6 | |
| Cases, n | 55 | 52 | 63 | 46 | |
| Person-years, n | 6844 | 6643 | 6515 | 6256 | |
| Follow-up, y | 5.5 | 5.3 | 5.1 | 5.0 | |
| Incidence, % | 6.5 | 7.8 | 9.6 | 7.3 | |
| Crude | 1.00 ref | 1.19 (0.80–1.77) | 1.47 (1.00–2.16) | 1.13 (0.74–1.70) | 0.58 |
| Model adjusted b | 1.00 ref | 1.04 (0.68–1.59) | 1.19 (0.76–1.85) | 0.84 (0.48–1.48) | 0.44 |
| Median, µg/d | 267 | 428 | 611 | 964 | |
| Cases, n | 53 | 60 | 41 | 52 | |
| Person-years, n | 7020 | 6020 | 6472 | 6145 | |
| Follow-up, y | 5.7 | 5.3 | 5.1 | 5.0 | |
| Incidence, % | 7.5 | 9.0 | 6.3 | 8.4 | |
| Crude | 1.00 ref | 1.21 (0.83–1.75) | 0.84 (0.56–1.27) | 1.13 (0.77–1.67) | 0.81 |
| Model adjustedb | 1.00 ref | 1.16 (0.78–1.70) | 0.82 (0.52–1.28) | 1.00 (0.61–1.63) | 0.74 |
| Median intake (mg/d) | 7.6 | 10.5 | 13.2 | 17.8 | |
| Cases, n | 51 | 61 | 41 | 53 | |
| Person-years, n | 6959 | 6728 | 6409 | 6161 | |
| Follow-up, y | 5.6 | 5.3 | 5.1 | 5.0 | |
| Incidence, % | 7.3 | 9.0 | 6.3 | 8.6 | |
| Crude | 1.00 ref | 1.24 (0.85–1.80) | 0.88 (0.58–1.33) | 1.16 (0.81–1.76) | 0.62 |
| Model adjustedb | 1.00 ref | 1.20 (0.80–1.81) | 0.81 (0.49–1.35) | 1.09 (0.58–2.05) | 0.97 |
aTest for trend based on ordinal variable containing median value for each quartile.
bAdjusted for age, sex, CVD risk score, family history of CVD, physical activity, total energy intake, fiber and total fat intakes.